MicroRNA and Human Bone Health

Vincent Ka-Fai Cheng,1 Philip Chun-Ming Au,1 Kathryn CB Tan,2 and Ching-Lung Cheung1,3

1Department of Pharmacology and Pharmacy, The University of Hong Kong, Pokfulam, Hong Kong
2Department of Medicine, The University of Hong Kong, Pokfulam, Hong Kong
3Centre for Genomic Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong

ABSTRACT

The small non-coding microRNAs (miRNAs) are post-transcription regulators that modulate diverse cellular process in bone cells. Because optimal miRNA targeting is essential for their function, single-nucleotide polymorphisms (SNPs) within or proximal to the loci of miRNA (miR-SNPs) or mRNA (PolymiRTS) could potentially disrupt the miRNA-mRNA interaction, leading to changes in bone metabolism and osteoporosis. Recent human studies of skeletal traits using miRNA profiling, genomewide association studies, and functional studies started to decipher the complex miRNA regulatory network. These studies have indicated that miRNAs may be a promising bone marker. This review focuses on human miRNA studies on bone traits and discusses how genetic variants affect bone metabolic pathways. Furthermore, studying the miRNAs’ signatures in secondary osteoporosis and osteoporotic medications such as teriparatide (TPTD) and denosumab (DMab) have provided valuable insight into clinical management of the disease. © 2018 The Authors. JBMR Plus Published by Wiley Periodicals, Inc. on behalf of the American Society for Bone and Mineral Research.

KEY WORDS: MICRORNA; OSTEOPOROSIS; METABOLISM; POLYMIRTS

Introduction

Osteoporosis is characterized by reduced bone strength and deteriorated bone microarchitecture. One-third of women and one-fifth of men worldwide, aged 50 years and older, are expected to experience osteoporotic fracture.1,2 The subsequent health care cost regarding hospitalization and related follow-up treatment is surging every year. In Europe, the health care cost resulting from osteoporosis is expected to increase by 10 billion euros over a 15-year period from 2010 to 2025.2,3 This would pose an immense financial burden to society, thus making osteoporosis treatment and prevention an important research area.

Currently, the usual approaches for screening and monitoring approaches for osteoporosis include the dual-energy X-ray absorptiometry (DXA) and FRAX score. Although DXA is the gold standard for osteoporosis diagnosis, predicting fracture based solely on bone mineral density (BMD) value has been unreliable.3,4 Moreover, the availability of DXA is very limited, especially in developing countries.5 On the other hand, although FRAX is a widely available web-based clinical risk assessment tool, its accuracy is limited by the exclusion of variables that are known to associate with fracture risks.6 Bone turnover markers (BTMs) such as serum procollagen N-terminal propeptide (P1NP) and serum C-terminal telopeptide of type I collagen (CTX) have emerged as useful tools for predicting and monitoring disease progression.7 In a recent meta-regression analysis involving 28,000 participants enrolled in 14 trials, changes in BTMs were significantly associated with risk of vertebral fracture.8 However, the association was only significant in vertebral fracture but not in other fractures. Moreover, most of the BTMs are subject to diurnal variation.9 Therefore, research efforts have been diverted to identifying novel blood-based bone biomarkers.

In the past decade, microRNAs (miRNAs) have been recognized as important regulators of bone metabolism. Compared with conventional BTMs, miRNAs often have a higher measurability and a more robust stability in body fluid.10 Therefore, they have a higher potential to be used as biomarkers for predicting and monitoring osteoporosis.11 Furthermore, miRNA-based therapy, such as Miravirsen and MRX34, have already entered clinical trials for treating liver diseases and cancer, respectively. In bone research, improved in vivo osteogenesis was observed after miRNA treatment, highlighting the potential use of miRNAs as a therapeutic agent.12

Research in miRNAs and bone biology has grown rapidly over the past years, and studies on the roles of miRNAs in basic cellular functions were reviewed recently.13,14 Eighty unique miRNAs were identified to associate with BMD, fracture, and osteoporosis in human studies (Supplemental Table S1). The current review will cover the advances in miRNA research on human osteoporosis.
from the following perspectives: 1) the effects of genetic variants and mutations on miRNA regulation in human; 2) the associations of miRNAs with osteoporosis and fractures; 3) the changes in miRNAs in response to osteoporosis medications.

**MicroRNA Biogenesis**

miRNAs are small non-coding single-stranded RNAs (19–24 bp). They regulate gene expressions by blocking translations and promoting degradations of target transcripts. There are at least 1400 mammalian miRNAs and 45,000 miRNAs target sites in human genome, covering 60% of the genes.\(^{14}\) Unlike the protein coding transcripts, these miRNAs are often coded in the intronic, intergenic, and polycistronic clustered regions.\(^{15}\)

During miRNA biogenesis, primary miRNAs (pri-miRNAs) can form multiple stem-loop structures in the nucleus after transcription. In nucleus, the pri-miRNA transcripts are trimmed into pre-miRNAs by Drosha-DGCR8 RNase complex and are exported to cytoplasm through exportin-5/GTP61. In cytoplasm, Dicer AGO2 and TRBP form a Dicer complex that further cleaves the pre-miRNAs into miRNA duplexes. During miRNA guided transcription, the pri-miRNA transcripts and each mRNA transcript can be regulated by different miRNAs, thus creating a complex regulatory network in numerous biological processes such as osteogenesis.

miRNAs were shown to promote osteogenic differentiation of mesenchymal stem cells (MSCs) by suppressing osteogenic inhibitors or by mediating major osteoblastic differentiation and signaling pathways.\(^{17}\) Human studies on miRNAs over the past 8 years have established links between miRNAs and various skeletal phenotypes including BMD and fracture. Furthermore, studies on miRNAs from blood and bone tissue have provided important insights into fundamental cellular processes such as the differentiation of bone cells (osteoblast and osteoclast).\(^{18}\)

**Effects of miRNA Polymorphisms on Skeletal Traits**

Successful pairing of miRNAs’ 5’ seed region with target miRNAs’ 3’ UTR targeting site depends on two factors: sequence complementary of the two and secondary structures of target miRNAs. Hence, SNPs within or proximal to the loci of miRNA (miR-SNPs) or mRNA (PolymiRTS) could potentially disrupt miRNA’s targeting on mRNA. The potential effects of miR-SNPs on skeletal traits have previously been discussed.\(^{19}\) Genetic variants in 7 miRNA families were reported to potentially affect skeletal traits, including miR-27a, miR-124, miR-125, miR-146a, miR-149, miR-196a2, and miR-2861. Although many SNPs in these loci were originally reported in cancer research, subsequent human studies have provided further evidence to support their potential roles in bone biology.

Variants in miR-146a, miR-149, and miR-196a2 were reported to associate with skeletal traits in multiple cohorts.\(^{20–22}\) Recent studies have further revealed several novel polymorphisms (let-7g, miR-140-5p, miR-149, miR-3679, miR-4274, miR-433, miR-499, and pri-miR-34b/c) that were significantly associated with skeletal traits.\(^{22–27}\) To date, 13 miR-SNPs were found to be associated with skeletal traits and they are summarized in Table 1.

**PolymiRTSs in FGF Signaling**

**FGF2**

Basic fibroblast growth factor (FGF2) is an essential mitogenic growth factor in the FGF polypeptide family. It is expressed in the majority of mesenchymal and bone-related cells, including chondrocytes, osteoblasts, adipocytes, and osteoclasts. FGF2 is expressed in limb buds during the developmental stage and controls the growth and patterning of limbs. In bone cells, by regulating parathyroid hormone (PTH) and bone morphogenetic protein 2 (BMP2)-induced bone formation,\(^{28,29}\) FGF2 promotes bone marrow stromal cell differentiation into osteoblast.\(^{30}\) In osteoclast, FGF2 is required for the regulation of receptor activator of NF-κB ligand (RANKL) and mesenchymal stem cell factor (M-SCF)-mediated differentiation.\(^ {31}\) Therefore, FGF2 is a crucial regulator during both bone development and remodeling.

Two single-nucleotide polymorphisms (SNPs; rs6854081 and rs1048201) at 3’ UTR of FGF2 were found to be associated with bone mineral density (BMD).\(^ {20,21}\) The minor allele G of rs6854081 was associated with low BMD in a cohort of white women (n = 2725).\(^ {20}\) The study demonstrated that FGF2 transcript containing allele rs6854081-T had a lower expression level in monocytes and B cells, and the allele was associated with higher BMD. The group further hypothesized that allele-T at rs6854081 would result in a higher binding affinity with miR-146a/b, hence suppressing FGF2 translation. Suppression of FGF2 would reduce osteoclastogenesis, which in turn leads to an increase in BMD. However, this causal relationship has not been experimentally validated yet. In another study, the minor allele T at rs1048201 was significantly associated with spine BMD in Han Chinese (n = 2339).\(^ {21}\) Subsequent bioinformatics analysis and experimental validation suggested that mir-196-3p could affect both FGF2 mRNA and protein levels. Using dual-luciferase assay and further Western blot confirmation in hFOB1.19 culture, they demonstrated rs1048201-C had a repressive effect on FGF2 expression. However, the Han Chinese study failed to replicate the association between rs6854081 and BMD, suggesting the effect of rs6854081 and rs1048201 on bone regulation might be ethnic specific.

**FGFRL1**

Given that FGF signaling has a ubiquitous role not only in skeletogenesis but also in the development and homeostasis of various cells, FGF pathway is tightly regulated. Fibroblast growth factor receptor like 1 (FGFRL1) is a non-tyrosine kinase that provides additional control over FGF ligands’ activation. FGFRL1 functions by binding to several FGFs, including FGF2/3/8.\(^ {32}\) Unlike the classical FGFRs, FGFRL1 is unable to cause downstream signal activation via tyrosine transphosphorylation.\(^ {33}\) The mechanism of FGFRL1 regulation is unclear, though it is thought to function as a decoy receptor for FGFs or as a modulator of intracellular signaling transducers.\(^ {33}\)

Studies have shown that FGFRL1 could both promote and inhibit cell differentiation,\(^ {33–35}\) although only a few studies have looked into the role of FGFRL1 in bone biology. A study on the differentiation of MSCs showed that FGFRL1 was a modulator of FGFRL1/2.\(^ {32}\) Interestingly, a more recent study demonstrated that during osteoblast differentiation, FGFRL1 acted as a positive regulator for FGR2, but on the flip side, it could also promote adipocyte differentiation with FGR1.\(^ {32}\) This dual-role nature of FGFRL1 supported further the idea of
FGFR1 being a modulator during cell lineage commitment, although in-depth research is still needed to uncover the mechanisms behind these regulations.

In a large-scale meta-analysis of 7 cohorts including white, Han Chinese, African Americans, and Hispanics, rs4647940 at FGFR1’s 3’ UTR was found to be significantly associated with BMD at the femoral neck.\(^{24}\) In this study, bioinformatics analyses showed that rs4647940 is located at an evolutionary conserved binding site of miR-140-5p. The binding affinity between miR-140-5p and FGFR1 3’ UTR was further validated

| Table 1. Genetic Variants Affecting miRNA Functions in Human |
| --- |
| **Gene** | **miRNA** | **SNP/mutation** | **Allele** | **Description** | **Subject** | **Ref. no.** |
| FGF2 | miR-146a/b | rs6854081 | G/T | Significant association with femoral neck BMD (\(p = 8.37 \times 10^{-3}\)) | White (discovery \(n = 997\); replication \(n = 1728\)) | (20) |
| | | | | and spine BMD (\(p = 1.53 \times 10^{-5}\)) | Chinese (discovery \(n = 1300\); replication \(n = 1039\)) | (21) |
| FGFRL1 | miR-140-5p | rs4647940 | C>G | Significant association with femoral neck BMD (\(p = 8.87 \times 10^{-12}\)) | Meta-analysis of 7 cohorts | (24) |
| 3’ UTR polymiRTSs | | | G>C | Allele G (Haplotype B) is associated with higher bone mass (\(p < 0.02\)) | White male (OP = 56 control = 59) | (26,41) |
| ON | miR-433 | rs1054204 | G>C | BMD was significantly increased in the INS/DEL or DEL/DEL group femoral neck (\(p = 0.018\), total left hip (\(p = 0.028\)), L1 to L4 (0.025), and intertrochanteric area (\(p = 0.018\)) | Chinese (\(n = 487\)) | (23) |
| COL1A2 | let-7g | rs3917 | INS/DEL | | | |
| Exonic mutation | WNT1 | miR-18a-3p | p.C218G (exon4) | Upregulated in mutation-positive subjects | 2 Finnish families with osteoporosis due to WNT1 p.C218G mutation (12 mutation-positive; 12 mutation-negative) | (49) |
| | | miR-223-3p | | | | |
| | | miR-22-3p | | | | |
| | | miR-21-3p | | | | |
| | | miR-34a-5p | | | | |
| | | miR-143-5p | | | | |
| | | miR-423-5p | | | | |
| | | miR-423-3p | | | | |
| miR-SNPs | pri-miR-34b/c | rs4938723 | T>C | CC and CT/CC associated with a significantly reduced risk of OP (CC versus TT: OR = 0.32; \(p < 0.001\); CT/CC versus TT: OR = 0.69; \(p = 0.016\)) | Chinese (\(n = 681\)) | (27) |
| | miR-146a | rs2910164 | C>G | miR-146a CG/ miR-196a2 TC combined genotype was more frequent in OVCF patients (OR = 5.163; \(p = 0.043\)) | Postmenopausal Korean women (\(n = 286\)) | (22) |
| | miR-196a2 | rs11614913 | T>C | TT genotype of miR-149a T>C may contribute to decreased susceptibility to OVCF (OR = 0.435; \(p = 0.014\)) | | |
| | miR-149a | rs2292832 | T>C | | | |
| | miR-499 | rs3746444 | A>G | miR-146aG/-149T/-196a2C/-449G allele combination may contribute to increased susceptibility of OVCF (OR = 35.01; \(p = 0.001\)) | OSTEOMED2 cohort (\(n = 2183\)) | (25) |
| | miR-3679 | rs6430498 | G>A | Significant association with low BMD (\(p = 0.001\)) | | |
| | miR-4274 | rs12512664 | G>A | | | |

3’ UTR polymiRTSs: Polymorphism in 3’ untranslated region of miRNAs and their TargetSites; miR-SNPs: Single nucleotide polymorphisms of microRNAs; BMD: Bone mineral density; OP: Osteoporosis; OVCF: Osteoporotic vertebral compression fracture; OR: Odds ratio; INS/DEL: Insertion/Deletion.

FGFR1 being a modulator during cell lineage commitment, although in-depth research is still needed to uncover the mechanisms behind these regulations. In a large-scale meta-analysis of 7 cohorts including white, Han Chinese, African Americans, and Hispanics, rs4647940 at FGFR1’s 3’ UTR was found to be significantly associated with BMD at the femoral neck.\(^{24}\) In this study, bioinformatics analyses showed that rs4647940 is located at an evolutionary conserved binding site of miR-140-5p. The binding affinity between miR-140-5p and FGFR1 3’ UTR was further validated
by dual luciferase assay. To test for the in vivo function of miR-145-5p, microinjection of dre-miR-140-5p into zebrafish embryo was performed, and it resulted in an absence of ceratobranchial cartilages and severe craniofacial malformation. This suggested FGFRL1 and miR-140-5p could play an important role in bone formation and development.

**PolymiRTSs in ECM Formation**

Bone extracellular matrix (ECM) proteins provide tensile strength and elasticity for bone tissue by serving as an essential framework for mineralization. Collagen type I contributes to 90% of the ECM proteins, whereas collagen type I alpha 2 (COL1A2) is a major component of collagen type I triple helix fiber.²⁶ The assembly of collagen fibers are aided by non-collagenous matrix proteins, such as osteonectin (ON).²⁷ ON is one of the most abundant non-collagenous matrix proteins. Besides matrix organization, ON promotes osteoblast differentiation and survival in MSCs while suppressing adipogenesis.²⁸,²⁹ Therefore, COL1A2 and ON are essential for proper bone formation and mineralization, and mutation in either of the genes could result in major skeletal disorders such as osteogenesis imperfecta.³⁰

Human studies on miRNAs and polymiRTSs of COL1A2 and ON has provided insight into the miRNA species that affect bone extracellular matrix (ECM). A study (N = 487) reported that an insertion/deletion (INS/DEL) polymorphism (rs3917) in the 3’ UTR of COL1A2 was associated with risk of osteoporosis.³¹ The study demonstrated a significant reduction in BMD in the INS/DEL or DEL/DEL group versus the INS/INS group; subsequent in vitro study using 48 patients’ primary osteoblast showed that let-7g could negatively regulate COL1A2 in osteoblast with INS/INS genotype but not with INS/DEL and DEL/DEL genotypes. Notably, the findings were contradictory: INS/INS genotype was associated with a reduced expression of COL1A2 in primary osteoblast, yet it was also associated with higher BMD in human. Additionally, the mineralization ability of the primary osteoblasts was not evaluated. Thus, further study is required to examine the mechanistic relation of rs3917 to bone metabolism.

For ON, rs1054204, which is located in the 3’ UTR of ON, was associated with BMD in middle-aged white men with idiopathic, low turnover osteoporosis (n = 56).³² Two haplotypes at the ON 3’ UTR were identified: haplotype A with a G allele at rs1054204 and haplotype B with a C allele at rs1054204. It was observed that rs1054204-C was associated with higher BMD. The finding was validated independently using in vivo mouse model. Mice with rs1054204-C had increased cortical bone area and ON expression. MiR-433 was suggested to be a potential regulator of ON. The expression of miR-433 was shown to be reducing during osteoblast differentiation, and direct interaction between miR-433 and rs1054204 was observed via ON 3’ UTR reporter constructs.²⁴

**MiRNAs in WNT1 Mutation**

Canonical WNT/β-catenin signaling is a well-established pathway regulating bone formation and remodeling. In vitro studies have identified multiple miRNA binding partners of key Wnt signaling components, such as LRP-6 (miR30e-5p), DKK1 (miR-152-3p, miR-335), and APC (miR-27a-3p, miR-142).²⁴,⁴⁻⁷ Although the effects of Wnt signaling components in bone have been widely studied, the relationships between various Wnt ligands and miRNAs in bone biology is still unexplored. WNT1 is one of the Wnt ligands. In human, monoallelic mutation at WNT1 would lead to inherited early onset of osteoporosis, whereas biallelic mutations would lead to osteogenesis imperfecta.³⁸

So far, the role of miRNA in monogenic bone diseases remained largely unexplored. A recent study investigated the relationship between serum miRNA profiles and BMD in individuals with heterozygous WNT1 p.C218G mutation.³⁹ The study was conducted in 24 subjects from two Finnish families, in which half of the subjects were mutation positive. In the mutation-positive subjects, p.C218G missense mutation resulted in early onset and progressive osteoporosis with normal levels of BTMs. The study showed that 6 miRNAs were significantly downregulated (miR-22-3p, miR-31-5p, miR-34a-5p, miR-143-5p, miR-423-3p, and miR-423-5p) in the osteoporotic subjects. MiR-31-5p had no known function in WNT1, but it was reported to be involved in osteogenesis.⁴⁰ MiR-423-3p/5p were not linked to bone metabolism or WNT signaling. For the remaining miRNAs, miR-22-3p, miR-34a-5p, and miR-143-5p were known to target WNT signaling molecules or bone-related genes such as RUNX2, Osterix, and WNT1.⁴¹ On the other hand, miR-18a-3p and miR-223-3p were found to be significantly upregulated. Among them, miR-223-3p was known to target bone-related genes.⁴²,⁴³ This Finnish study was the first to evaluate miRNA profiles in WNT1 heterozygous mutation subjects. However, whether these differentially expressed miRNAs could serve as bone biomarkers is still unclear and further investigations are warranted.

**MiR-SNPs**

Genetic variants affecting miRNAs’ functions were not found only in target mRNA transcripts. The number of reports on miR-SNPs, ie, SNPs located within the pri/pre-miRNA and promoter sequence, have been increasing over the past years. MiR-SNPs could alter miRNA maturation and its target binding affinity. Certain variants could also trigger alternative cleavage for miRNAs’ biogenesis enzymes, leading to abnormal miRNA expression or even new miRNA isoforms.⁴⁴

**MiR-34b/c and TP53**

MiR-34b and MiR-34c belongs to the miR-34 family, which consists of miR-34a, miR-34b, and miR-34c. MiR-34b and miR-34c shares the same primary transcript at chromosome 11q23, whereas miR-34a is located at chromosome 1p36. Members of the miR-34 family are downstream targets of TP53, a well-known cancer suppressor.⁴⁵ The miR-34 family are involved in a wide range of cellular process.⁴⁶ Targets of miR-34 include components of major bone signaling pathways such as Notch and Wnt signaling.⁴⁷ In vivo mouse models showed that miR-34c regulated osteoclast differentiation by targeting multiple Notch components including Notch1/2 and Jag. Additionally, miR-34b was reported to play a causal role in osteosarcoma.⁴⁸ MiR-34a was associated with WNT1 mutation in the human study aforementioned and miR-34a KO mice exhibited elevated bone resorption and reduced bone mass.⁴⁹

rs4938723 is located at the CpG region of pri-miR-34b/c promoter. This variant of miR-34b/c was known to associate with cancers.⁵⁰,⁵¹ In a recently study, rs4938723 miR-34b/c was also found to be associated with osteoporotic risk.²⁷ The study investigated the association of mutations at rs4938723 and TP53 (Arg72Pro) with osteoporosis among 318 osteoporosis patients and 371 controls. A significant reduction of osteoporotic risk was
observed for homozygous CC at rs4938723 (odds ratio [OR] = 0.35, 95% confidence interval [CI] 0.19–0.64; p < 0.001), whereas the TP53 Arg72Pro CC genotype carriers showed a significantly increased risk of osteoporosis (OR = 2.21, 95% CI 1.45–3.37; p < 0.001).

MiR-146a, 149, 196a, and 499

Rs2910164 (miR-146a), rs2292832 (miR-149), rs11614913 (miR-196a-2), and rs3746444 (miR-499) are known to associate with various diseases. In bone, miR-196a and miR-146a were involved in osteoblast and osteoclast differentiation, whereas miR-146a and miR-149 were linked to rheumatoid arthritis (RA) and osteoarthritis (OA), respectively. The association of these SNPs with osteoporotic fracture was evaluated in a recent study composed of 286 postmenopausal Korean women (57 with osteoporotic vertebral compression fractures [OVCFs], 55 with non-OVCFs, and 174 healthy controls). It was reported that a combination of genotypes miR-146aG/-149T/-196a2C/-449G was associated with increased OVCF risk (OR = 35.01; 95% CI 1.919–638.6, p = 0.001). In contrast, miR-149a T/T was associated with a reduced risk (OR = 0.435; 95% CI 0.22–0.85, p = 0.014). Although these SNP-containing miRNAs were seldom reported in other human studies of bone fractures, investigations using cell or animal models have supported their significance in bone metabolism.

MiR-146

The miR-146 family consists of miR-146a-3p and –b and they are both linked to polymiRTSs of FGF2 as discussed previously. MiR-146a, located at 5q33.3, is expressed in cartilage and femur and other non-skeletal tissues including liver, breast, and hematopoietic cells. During bone formation, miR-146a plays a positive role by targeting SMAD4 in the TGF-β signaling, which in turn suppresses SOX9 and increases RUNX2 expression. Increased miR-146a expression contributes to osteoarthritis, which was postulated to be caused by reduced chondrocyte survival via TGF-β suppression. On the other hand, miR-146b, located at 10q24, drives MSCs toward adipogenesis. In human skeletal stem cells, miR-146b is downregulated during chondrogenic differentiation. High level of miR-146b contributes to osteoarthritis by suppressing SOX5, which is an important transcription factor in chondrogenesis.

MiR-196

The miR-196 family is located within the HOX clusters. HOXs are major regulators of skeletal patterning and limb development and they coordinate morphogen signaling pathways such as BMP and TGF. MiR-196 regulates skeletal development by orchestrating the level of HOX proteins in a temporal spatial manner. For miR-196a, it was shown to drive MSCs toward osteoblast lineage by targeting HOXC8. The 3p strand, miR-196a-3p, was also shown to interfere with FGF2 expression in a human study on FGF2 polymiRTS. Within the miR-196a-2 sequence, like many other miRNAs, rs11614913 was first reported to be associated with cancer susceptibility. Recent in vivo studies using mouse model revealed a co-regulatory mechanism of the miR-196 family and HOX genes in controlling vertebral morphology. Using data from the GEFOS consortium and the Rotterdam study, significant associations between rs11614913 and both lumbar spine and femoral neck BMD were reported in female subjects.

MiR-149 and 499

MiR-149 and miR-499 have not been shown to be directly involved in bone metabolism. Previous human and in vitro studies reported their roles in inflammatory response: MiR-149 and 499 are both involved in the suppression of inflammatory cytokines including IL-1β, IL-6, and TNF-α. The SNP rs3746444 in miRNA-499 was shown to associate with rheumatoid arthritis in a meta-analysis. MiR-149 was downregulated in an in vitro osteoarthritis model upon inflammatory stimulation. The SNP rs2292832 in miR-149 was shown to be associated with breast cancer and ischemic stroke, however, its association with BMD in human has not been reported in literature so far.

MiR-3679 and 4274

MiRNA species in skeletal research often lack functional characterization. MiR-3679 and miR-4272 are novel miRNAs identified from a cohort of Spanish postmenopausal women. The allele A of rs6430498 in pre-miR-3679 and rs12512664 in pre-miR-4234 were associated with decreased BMD at femoral neck in the OSTOMED2 cohort (n = 2183). The study also observed overexpression of both miR-3679 and miR-4234 in trabecular bone samples from osteoporotic fracture patients. In functional studies, miR-3679 inhibition was shown to increase matrix mineralization by 10% in primary hOB cells. Given that studies on miR-3679 and miR-4274 in bone metabolism are scarce, further validation for the mechanistic roles of miR-3679 and miR-4274 as well as their effects is needed.

MiRNAs in Human Osteoporosis Studies

Human osteoporosis studies on miRNAs thus far have identified 57 miRNA families that were potentially related to bone metabolism (Supplemental Table S1). Studies on the same pathological conditions often detected partially overlapping or, in some cases, completely new miRNA signatures, thus increasing the number of novel miRNAs that could potentially affect bone metabolism. However, many still need further characterization. In the following section, miRNAs that were identified across multiple human studies will be reviewed (Table 2).

MiR-21

MiR-21 is one of the most frequently identified miRNA species in human bone researches. Over the past years, independent studies have suggested that changes in circulating miR-21 levels are significantly associated with osteoporotic risk. An early study found that miR-21 levels were elevated in serum (n = 30 per group) and bone tissue (n = 20 per group) of osteoporotic subjects. Similarly, another study showed a significant increase in circulating miR-21-5p in osteoporotic subjects (n = 7 per group). Its expression was also upregulated in isolated bone tissues, primary cultures of osteoblast and osteoclast. These results suggested that miR-21 was positively correlated with risk of osteoporosis. However, other studies reported opposite findings. In a study of Chinese postmenopausal women with osteopenia and osteoporosis, plasma miR-21 level was significantly reduced (n = 40 per group). A later study on the osteoporotic individuals in the Greek population also reported that decrease in serum miR-21-5p was significantly associated with increased risk of vertebral fracture.
and low bone mass. These contradictory results in human studies may be attributable to relatively small sample sizes.

In vitro studies showed that miR-21 had a role in both osteoblast and osteoblast biology. In osteoclast, miR-21 was shown to promote osteoclastogenesis by downregulating PDCD4, which in turn de-represses c-Fos, a key transcription factor for macrophage-osteoclast differentiation. Similarly, a recent study using miR-21 KO mouse model

| miRNA | Level changes in primary osteoporotic subjects | Population | Sample size | Phenotypes and targets in related functional studies | Ref. no. |
|-------|-----------------------------------------------|------------|-------------|-----------------------------------------------------|---------|
| miR-21 | Increase Serum and bone tissue | German | n = 30 per group (serum); n = 20 per group (bone tissue) | PDCD4 (osteoclast, mouse); PI3K/β-catenin pathway (human umbilical cord MSCs) | (89) |
|        | Decrease Serum; bone tissue; isolated osteoblast osteoclast | Chinese postmenopausal women | n = 40 per group (osteoporosis versus osteopenia versus normal) | Stimulate osteogenesis (hPDLSCs) | (92) |
|        | Serum level is associated with increased vertebral fracture and lower bone mass | Greek postmenopausal women | n = 70 versus 30 control |                                    | (93) |
| miR-23-3p | Increase Serum and bone tissue | German | n = 30 per group (serum); n = 20 per group (bone tissue) | Reduce bone mass (mouse—gain of function) | (89) |
|        | Decrease Serum level is associated with increased vertebral fracture and lower bone mass | Greek postmenopausal women | n = 70 versus 30 control | Stimulate osteogenesis (hBMSCs) | (93) |
| miR-100 | Increase Serum and bone tissue | German | n = 30 per group (serum); n = 20 per group (bone tissue) | BMPR2, SMAD1 (mouse MSC) | (89) |
|        | Decrease Serum; bone tissue; isolated osteoblast osteoclast | German | n = 7 per group |                                    | (91) |
| miR-124 | Increase Serum and bone tissue | German | n = 30 per group (serum); n = 20 per group (bone tissue) | Dlx2,3,5 (mouse MSC) | (89) |
|        | Decrease Serum level is associated with increased vertebral fracture and lower bone mass | Greek postmenopausal women | n = 70 versus 30 control | NFATc1, Rab34 (mouse bone marrow monocytes) | (93) |
|        | Serum and bone tissue | German | n = 30 per group (serum); n = 20 per group (bone tissue) |                                    | (89) |
|        | Serum; bone tissue; isolated osteoblast osteoclast | German | n = 7 per group |                                    | (91) |
| miR-125b | Increase Serum | Spanish | n = 12 versus 15 osteoarthritic control | Cbfβ (C3H10T1/2 cells) | (108) |
|        | Expression in bone biopsy | Postmenopausal women (Array Express database) | n = 27 versus 39 control |                                    | (109) |
| miR-133 | Increase Serum | White (US) postmenopausal women | n = 10 per group | Osteoclastogenesis (R264.7, THP-1 cells) | (113) |
|        | Plasma | Chinese postmenopausal women | n = 40 per group (osteoporosis versus osteopenia versus normal) | Increased bone mass (knockout mouse) | (92) |
|        | Serum | Chinese postmenopausal women | n = 10 per group |                                    | (114) |
also supported the role of miR-21 as an osteoclastogenic promoter.\(^{(99)}\) MiR-21\(^{-}(+)\) mice showed protection against age-related osteopenia with increased PDCD4 level and trabecular bone mass accrual despite the elevated serum RANKL. However, in osteoblast differentiation, the role of miR-21 remained unclear. MiR-21 was reported to stimulate osteoblastic differentiation of MSCs through the PI3K/β-catenin pathway in human umbilical cord MSCs.\(^{(96)}\) Yet, in human periodontal ligament stem cells (hPDLCs), decreased expression of miR-21 was observed during osteogenesis.\(^{(97)}\) At this point, evidence from functional studies showed consistently a positive role of miR-21 in osteoblastogenesis; however, its role in osteoblast differentiation remained controversial.

**MiR-23-3p**

For miR-23-3p, thus far, no clear conclusion on the role of miR-23 could be drawn from human studies. Seeliger and colleagues showed an increased miR-23a-3p level in both serum and bone tissue of osteoporotic patients.\(^{(89)}\) However, a recent study of osteoporotic postmenopausal women (\(n = 70\)) versus control (\(n = 30\)) yielded conflicting results, in which circulating miR-23a-3p was significantly lower in individuals with low bone mass.\(^{(93)}\)

In vitro study on human bone marrow mesenchymal stem cells (hBMSCs) revealed that increased miR-23a/b expression could promote osteoblastic differentiation.\(^{(98)}\) Moreover, it was further shown in vivo that continuous stimulation on differentiation could eventually lead to bone mass reduction, where increased level of miR-23a in osteoblast could promote its terminal differentiation to osteocyte.\(^{(99)}\) Mice with gain-of-function mutation of miR-23a cluster (Col1a1-miR-23aC) appeared to have lower bone mass. Such phenotype could be explained by a reduced osteoblast number and mineralized surface as well as an increased number of osteocytes.

**MiR-100**

After the identification of miR-100 in an early human study of osteoporotic serum and bone tissue samples,\(^{(89)}\) a subsequent study conducted by the same group demonstrated further that osteoporotic patients had a significant upregulation of miR-100-5p in both isolated osteoblast and osteoclast.\(^{(91)}\) In ex vivo cultures of patients’ osteoblast, higher miR-100-5p expression was observed during a 14-day culture period. In osteoclast, a significant increase in miR-100-5p expression was observed after 28 days of culture. Furthermore, the study demonstrated a strong inverse correlation between miR-100-5p expression in bone tissue and BMD at the femoral neck. These results suggested that an overall increase in miR-100-5p level might lead to bone loss.

An independent in vitro study of MSC revealed that miR-100 expression was reduced during osteoblast differentiation.\(^{(100)}\) Overexpression of miR-100 in MSC was shown to inhibit osteogenic differentiation by acting as an attenuator for key signaling molecules in osteogenic differentiation, including morphogenetic protein receptor type II (BMPR2) and SMAD1.\(^{(100,101)}\) On the other hand, the role of miR-100 in osteoclastogenesis has yet to be studied, and the interaction between different bone cells in vivo environment under the effect of miR-100 is still largely unknown. So far, the evidence has been consistent that miR-100 could inhibit bone formation.

**MiR-124**

Human studies shown that serum miR-124 levels were elevated in patients with low bone mass.\(^{(89,93)}\) MiR-124 could negatively regulate osteoblast formation by targeting essential osteogenic inducers, including Dlx2, Dlx3, and Dlx5. Moreover, expression of miR-124 decreased during osteoblast differentiation and over-expressing miR-124 mimic drove MSC to adipogenic differentiation.\(^{(102)}\) MiR-124 also targeted essential transcription factor for osteoclastogenesis (NFATc1)\(^{(103)}\) and major regulator of secretory lysosomes (Rab27a),\(^{(104,105)}\) which resulted in suppressing monocyte proliferation and differentiation.\(^{(105)}\) Besides bone cells, miR-124 was also shown to inhibit myogenic differentiation in MSC, which would potentially lead to increased risk of fracture in elderly by escalating muscle loss.\(^{(106)}\) Overall, miR-124 exhibited inhibitory effects on stem cell differentiation. Additional evidence from a recent study that an increase in miR-124 expression was observed in aged skin cells\(^{(107)}\) suggests miR-124 might play a role in diverse aging processes as well.

**MiR-125b**

Like miR-100 and miR-124, miR-125b was suggested to exert inhibitory effect on osteogenesis. Multiple studies reported an increased circulating miR-125b expression in osteoporotic patients.\(^{(89,91,108,109)}\) MiR-125b-5p level was found to be inversely correlated with BMD at the femoral head, with an increased expression being observed in osteoblast and osteoclast from osteoporotic patients.\(^{(91)}\) When comparing the circulating miRNAs in patients with osteoporotic fracture with those in osteoarthritic controls, circulating miR-125b-5p was also significantly upregulated in the osteoporotic fracture group.\(^{(108)}\)

To date, the functional role of miR-125b in bone metabolism remained largely unknown. In C3H10T1/2 cells, overexpression of miR-125b inhibited osteoblast differentiation by targeting Cbß, a key transcription osteogenic inducer, and in turn reduced Runx2 expression.\(^{(110)}\) However, this effect was not observed in another study using human MSCs.\(^{(111)}\) No study so far has evaluated miR-125b’s role in osteoclastogenesis.

**MiR-133**

Because of estrogen deficiency and increased calcium loss, postmenopausal women are more susceptible to osteoporosis and possess a higher fracture risk than men.\(^{(112)}\) and miRNAs may play a role in postmenopausal osteoporosis. Association between miR-133a and BMD variation in osteoporotic postmenopausal women has been reported in multiple studies. By measuring the miRNA expression in circulating monocytes in white postmenopausal women, Wang and colleagues found a significant increase in miR-133a expression in low BMD group.\(^{(113)}\) Using bioinformatics analysis, osteoblast-related genes, such as CKCL11, CXCR3, and SLC39A1, were found to be potential downstream targets. Two subsequent studies in Chinese postmenopausal women also reported increased miR-133a levels in serum and plasma of low BMD group.\(^{(92,114)}\)

Liz and colleagues provided evidence that miR-133a could contribute to RANKL-induced osteoclast differentiation.\(^{(114)}\) By overexpressing miR-133a in R264.7 and THP-1 cells, expressions of osteoclastogenesis markers (NFATc1, c-Fos, and TRAP) were induced, whereas in miR-133a knockdown, expressions of these markers were suppressed. Similarly, in ovariectomized rats, miR-133a knockdown led to a significant increase in lumbar spine BMD. A study on arterial calcification provided clues for the effects of miR-133a on osteoblast. Overexpression of miR-133a inhibited transdifferentiation of vascular smooth muscle cells into osteoblast-like cell by targeting RUNX2 directly.\(^{(115)}\) Taken
together, these studies suggested that miR-133a could promote bone resorption and potentially inhibit bone formation.

Other miRNAs such as miR-194 and miR-19a were also proposed to be biomarkers for postmenopausal osteoporosis. However, there was no functional study or replication study conducted, thus their roles in bone metabolism remained inconclusive.

**MiRNAs in Secondary Osteoporosis**

**Glucocorticoid**

Glucocorticoid-induced osteoporosis (GIO) is the most common and severe form of secondary osteoporosis. A recent study evaluated the mRNA and miRNA levels in bone samples from Cushing’s disease patients with endogenous hypercortisolism. Elevated cortisol level is known to associate with accelerated bone loss in both men and women. In line with current understanding, among the hypercortisolism patients, bone marker genes, such as RUNX2, BGLAP, and ALPL, were downregulated, whereas expressions of Wnt-signaling antagonists were found increased. Furthermore, miRNAs that could impair bone formation (miR-34a-5p, miR-125b-5p and miR-188-3p) were also found upregulated.

**Autoimmune disorders**

Glucocorticoid therapy used in treating autoimmune diseases, such as inflammatory bowel disease (IBD) and systemic lupus erythematosus (SLE), could lead to osteoporosis. IBD patients are known to have elevated proinflammatory circulating cytokine and increased risk of fracture. A study investigating the miRNA expressions in peripheral immune cells of ulcerative colitis patients with low BMD found that miR-19a was significantly associated with inflammatory marker IL-13. MiR-19a was previously found to be upregulated in postmenopausal osteoporosis. However, whether miR-19a played a role in inflammation-mediated bone metabolism is still unclear and it requires further study.

SLE is a complex immune disorder, and osteoporosis is a well-known comorbidity of SLE. MiR-148a was found overexpressed in T cells of lupus patients. Because miR-148a is known to directly suppress MAFB, a repressor for RANKL-induced osteoclastogenesis, increased miR-148a could de-repress osteoclast differentiation and potentially contribute to bone loss. In fact, Peng and colleagues found an increase in miR-148a expression in CD14+ peripheral blood mononuclear cells among lupus patients with low BMD. Additionally, CD14+ PBMC from these patients also possessed increased TRAP activity, highlighting the potential role of miR-148a in enhancing osteoclastogenesis.

**Type 2 diabetes**

Type 2 diabetes (T2D) patients often have higher BMD and increased fracture risk both at the same time. This could be because of poor bone quality, another important determinant of bone strength. In a study on the relationship between diabetic bone fracture and miRNAs, Ursula and colleagues investigated the circulating miRNA profiles of 80 postmenopausal women with T2D and osteoporosis and found that miR-550a-5p, miR-96-5p, miR-382-3p, and miR-181c-5p were associated with fracture risk. The finding suggested that aging acceleration was involved and it could be caused by increasing cellular oxidative stress and dysregulating lipid and glucose metabolism in human body. They further investigated the effects of miR-550a-5p and miR-382-3p on bone metabolism and found that while both miR-382-3p and miR-550a-5p impaired adipogenic differentiation, respectively they significantly enhanced and inhibited osteogenic differentiation in human adipose-derived stem cells (hASCs).

To date, there are only a handful of human studies investigating the miRNA signatures of secondary osteoporosis. More studies on the secondary causes of osteoporosis, such as hyperthyroidism, chronic liver diseases, and hematological disorders, are needed.

**MiRNAs in Antiosteoporosis Treatment**

Teriparatide (TPTD) and denosumab (Dmab) are currently two of the most potent anti-osteoporotic medications. Teriparatide is an anabolic agent that mimics human parathyroid hormone, which promotes calcium absorption and bone formation. Denosumab is an antiresorptive agent that specifically binds to RANKL, prevents RANK activation and osteoclast formation, and results in decreased bone resorption.

The changes in miRNA expressions during teriparatide and denosumab treatments were recently investigated. Because the two drugs have opposite effects, distinct miRNA profiles were observed in serum from postmenopausal women who were undergoing either TPTD or Dmab treatment.

In the TPTD treatment group, miR-133a and miR-33 levels were significantly decreased after 3 to 12 months of treatment. As shown in other human studies, miR-133a could promote osteoclast differentiation, and its level was correlated with low BMD in postmenopausal women. It was also shown that miR-133a could hamper bone formation by targeting RUNX2. MiR-33, on the other hand, was involved in mechano-induced osteoblast differentiation, but its association with BMD has yet to be reported.

In the Dmab treatment group, no significant change in miRNA levels were observed during treatment. However, after denosumab treatment was ceased, a significant change in miRNA levels took place, and this change might contribute to the increased fracture risk observed among patients after stopping denosumab treatment. In individuals who suffered these rebound-associated fractures, significantly lower circulating miR-503 and miR-222 were observed. These changes were associated with a drastic increase in the expressions of osteoclastogenesis-related genes RANK (13-fold) and CTSK (2.6-fold), indicating a significant rebound in osteoclast activity after denosumab discontinuation. Functionally, miR-503 was shown to suppress Smurf1 expression and promote bone formation. On the other hand, miRNA-222 could be a negative regulator of osteogenesis because inhibition of miR-222 was shown to enhance fracture healing. Although the underlying mechanisms of these changes remained unknown, these discoveries would serve as an important starting point for further investigations into the roles of miRNAs in anti-osteoporotic treatment.

**Conclusion**

Human studies on the relationship between miRNAs and bone metabolism have provided valuable insights into the roles of
miRNAs in osteoporosis. Over the years, using bone tissues, serum, plasma, and circulating blood cells of individuals with different skeletal conditions, population-based studies have been continuously updating the library for bone metabolism–related miRNAs. Although the clinical translation of miRNAs in anti-osteoporotic treatment is still at its infancy and many of the miRNAs still require extensive validation and characterization, current research efforts have already kick-started the development of miRNA-based fracture risk assessment tools like osteomiR, which was shown to effectively reduce screening and monitoring costs for osteoporosis. Yet, because of limited sample sizes and unreliable bone measurements, identification of clinically useful miRNAs for osteoporosis management remains a challenging task. Large-scale collaborative effort is warranted for a larger study sample and to provide a consensus on the methodology in human studies, in hopes of delineating the complex relationship between miRNAs and bone metabolism.

Disclosures

All authors state that they have no conflict of interest regarding this manuscript.

Acknowledgments

All authors were involved in drafting or revising the content. We thank our colleagues for significant intellectual contribution to the manuscript and apologize to investigators whose relevant work was omitted due to space limitations.

References

1. Melton LJ 3rd, Chrischilles EA, Cooper C, Lane AW, Riggs BL. Perspective. How many women have osteoporosis? J Bone Miner Res. 1992;7(9):1005–10.
2. Melton LJ 3rd, Atkinson EJ, O’Connor MK, O’Fallon WM, Riggs BL. Bone density and fracture risk in men. J Bone Miner Res. 1998;13(12):1915–23.
3. Small RE. Uses and limitations of bone mineral density measurements in the management of osteoporosis. MedGenMed. 2005;7(2):3.
4. Marshall D, Johnnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ. 1996;312(7041):1254–9.
5. Mithal A, Bansal B, Kyer CS, Ebeling P. The Asia-Pacific Regional Audit-Epidemiology, Costs, and Burden of Osteoporosis in India 2013: a report of International Osteoporosis Foundation. Indian J Endocrinol Metab. 2014;18(4):449–54.
6. Silverman SL, Calderon AD. The utility and limitations of FRAX: a US perspective. Curr Osteoporos Rep. 2010;8(4):192–7.
7. Shetty S, Kapoor N, Bondu JD, Thomas N, Paul TV. Bone turnover markers: emerging tool in the management of osteoporosis. Indian J Endocrinol Metab. 2016;20(4):195–9.
8. Bauer DC, Black DM, Bouxsein ML, et al. Treatment-related changes in bone turnover and fracture risk reduction in clinical trials of anti-resorptive drugs: a meta-regression. J Bone Miner Res. 2018;33(4):634–42.
9. Redmond J, Fulford AJ, Jarjou L, Zhou B, Prentice A, Schoenmakers JD. Dnmal rhythms of bone turnover markers in three ethnic groups. J Clin Endocrinol Metab. 2016;101(8):3222–30.
10. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008;105(30):10513–8.
11. Hackl M, Heilmeyer U, Weilner S, Grillari J. Circulating microRNAs as novel biomarkers for bone diseases—complex signatures for multifactorial diseases? Mol Cell Endocrinol. 2016;432:83–95.
12. Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017;16(3):203–22.
13. Valenti MT, Dalle Carbonare L, Mottes M. Role of microRNAs in progenitor cell commitment and osteogenic differentiation in health and disease (Review). Int J Mol Med. 2018;41(5):2441–9.
14. Taipaleenmaki H. Regulation of bone metabolism by microRNAs. Curr Osteoporos Rep. 2018;16(1):1–12.
15. Saini HK, Griffiths-Jones S, Enright AJ. Genomic analysis of human microRNA transcripts. Proc Natl Acad Sci U S A. 2007;104(45):17719–24.
16. Ha M, Kim VN. Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol. 2014;15(8):509–24.
17. Weilner S, Skalicky S, Salzer B, et al. Differentially circulating miRNAs after recent osteoporotic fractures can influence osteogenic differentiation. Bone. 2015;79:43–51.
18. McAlinden A, Im Gl. MicroRNAs in orthopaedic research: disease associations, potential therapeutic applications, and perspectives. J Orthop Res. 2018;36(1):33–51.
19. Dole NS, Delany AM. MicroRNA variants as genetic determinants of bone mass. Bone. 2016;84:57–68.
20. Lei SF, Papasian CJ, Deng HW. Polymorphisms in predicted miRNA binding sites and osteoporosis. J Bone Miner Res. 2011;26(1):72–8.
21. Zhu DL, Guo Y, Zhang Y, et al. A functional SNP regulated by miR-196a-3p in the 3′UTR of FGF2 is associated with bone mineral density in the Chinese population. Hum Mutat. 2017;38(6):723–35.
22. Ahn TK, Kim JO, Kumar H, et al. Polymorphisms of miR-146a, miR-149, miR-196a-2, and miR-499 are associated with osteoprotective vertebral compression fractures in Korean postmenopausal women. J Orthop Res. 2018;36(1):244–53.
23. Jiang ZS, Hao ZH. An insertion/deletion polymorphism within the 3′ untranslated region of COL1A2 confers susceptibility to osteoporosis. Mol Med Rep. 2016;14(5):4415–21.
24. Niu T, Liu N, Zhao M, et al. Identification of a novel FGFR1 microRNA target site polymorphism for bone mineral density in meta-analyses of genome-wide association studies. Hum Mol Genet. 2015;24(16):4710–7.
25. De-Ugarte L, Caro-Molina E, Rodriguez-Sanz M, et al. SNPs in bone-related miRNAs are associated with the osteoporotic phenotype. Sci Rep. 2017;7(1):516.
26. Dole NS, Kapinas K, Kessler CB, et al. A single nucleotide polymorphism in osteonectin 3′ untranslated region regulates bone volume and is targeted by miR-433. J Bone Miner Res. 2015;30(4):723–32.
27. Jia F, Sun R, Li J, Li Q, Chen G, Fu W. Interactions of Pri-miRNA-34b/c and TP53 polymorphisms on the risk of osteoporosis. Genet Test Mol Biomarkers. 2016;20(7):398–401.
28. Sabbieti MG, Agas D, Xiao L, et al. Endogenous FGF-2 is critically important in PTH anabolic effects on bone. J Cell Physiol. 2009;219(1):143–51.
29. Naganawa T, Xiao L, Coffin JD, et al. Reduced expression and function of bone morphogenetic protein-2 in bones of Fgfr2 null mice. J Cell Biochem. 2008;103(6):1975–88.
30. Xiao L, Sobue T, Esliger A, et al. Disruption of the Fgf2 gene activates the adipogenic and suppresses the osteogenic program in mesenchymal marrow stromal stem cells. Bone. 2010;47(2):360–70.
31. Chikazu D, Katagiri M, Ogasawara T, et al. Regulation of osteoclast differentiation by fibroblast growth factor 2: stimulation of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor expression in osteoblasts and inhibition of macrophage colony-stimulating factor function in osteoclast precursors. J Bone Miner Res. 2001;16(11):2074–81.
32. Kahkonen TE, Iivaska KK, Jiang M, Buki KG, Vaananen HK, Harkonen PL. Role of fibroblast growth factor receptors (FGFR) and FGFR-like-1 (FGFR1) in mesenchymal stromal cell differentiation to osteoblasts and adipocytes. Mol Cell Endocrinol. 2018;461:194–204.
33. Yang X, Steinberg F, Zhuang L, Bessey R, Trueb B. Receptor FGFR1 does not promote cell proliferation but induces cell adhesion. Int J Mol Med. 2016;38(1):30–8.
34. Steinberg F, Zhuang L, Beyeler M, et al. The FGFR1L receptor is shed from cell membranes, binds fibroblast growth factors (FGFs), and antagonizes FGF signaling in Xenopus embryos. J Biol Chem. 2010;285(3):2193–202.

35. Silva PN, Altamentova SM, Kilkenny DR, Rocheleau JV. Fibroblast growth factor receptor like-1 (FGFR1L) interacts with SHP-1 phosphatase at insulin secretory granules and induces beta-cell ERK1/2 protein activation. J Biol Chem. 2013;288(24):17859–70.

36. Vignoret-Carrin S, Garnero P, Delmas PD. The role of collagen in bone strength. Osteoporos Int. 2006;17(3):319–36.

37. Termine JD, Kleinman HK, Whitson SW, Conn KM, McGarvey ML, Martin GR. Osteonectin, a bone-specific protein linking mineral to collagen. Cell. 1981;26(1 Pt 1):99–105.

38. Delany AM, Hankenson KD. Thrombospondin-2 and SPARC/osteonectin are critical regulators of bone remodeling. J Cell Commun Signal. 2009;3(3–4):227–38.

39. Nie J, Sage EH. SPARC functions as an inhibitor of adipogenesis. J Cell Commun Signal. 2009;3(3–4):247–54.

40. Mendoza-Londono R, Fahiminiya S, Majewski J, et al. Recessive Notch ligand delta-like 1 impairs CD15+/CD133+ tumor-propagating cells and supports neural differentiation in medulloblastoma. PLoS One. 2011;6(9):e24584.

41. Delany AM, McMahon DJ, Powell JS, Greenberg DA, Kurland ES. Osteonectin/SPARC polymorphisms in Caucasian men with idiopathic osteoporosis. Osteoporos Int. 2008;19(7):969–78.

42. Xu Y, Chen B, George SK, Liu B. Downregulation of MicroRNA-152 contributes to high expression of DKK1 in multiple myeloma. RNA Biol. 2015;12(1):1342–22.

43. Zhang J, Tu Q, Bonewald LF, et al. Effects of miR-335-5p in modulating osteogenic differentiation by specifically down-regulating Wnt antagonist DKK1. J Bone Miner Res. 2011;26(8):1953–63.

44. Wang J, Guan X, Guo F, et al. miR-30e reciprocally regulates the differentiation of adipocytes and osteoblasts by directly targeting low-density lipoprotein receptor-related protein 6. Cell Death Dis. 2013;4:e845.

45. Wang T, Xu Z. miR-27 promotes osteoblast differentiation by modulating Wnt signaling. Biochem Biophys Res Commun. 2010;402(2):186–9.

46. Hu W, Ye Y, Zhang W, Wang J, Chen A, Guo F. miR-1423p promotes osteoblast differentiation by modulating Wnt signaling. Mol Med Rep. 2013;7(2):689–93.

47. Chen C, Peng Y, Peng Y, Peng J, Jiang S. miR-133a-sp inhibits T3-L1 adipogenesis through activation of canonical Wnt/beta-catenin signaling. J Mol Endocrinol. 2014;52(3):311–20.

48. Fahimiya R, Majewski J, Mort J, Moffatt P, Glorieux FH, Rauch F. Idiopathic osteoporosis. Osteoporos Int. 2008;19(7):969–78.

49. Weilner S, Schraml E, Wieser M, et al. Secreted microvesicular miR-34a suppresses osteoclasts and osteoporosis through Wnt/β-catenin signaling. J Mol Endocrinol. 2010;44(1):98–104.

50. Kaur K, Vig S, Srivastava R, et al. Elevated hepatic miR-22-3p expression impairs glucose homeostasis by silencing the Wnt-responsive transcription factor Tcf7. Diabetes. 2015;64(11):3659–69.

51. Fan C, Jia L, Zheng Y, et al. MiR-34a promotes osteogenic differentiation of human adipose-derived stem cells via the RBP2/NOTCH1/CYCLIN D1 coregulatory network. Stem Cell Reports. 2016;7(2):236–48.

52. Li E, Zhang J, Yuan T, Ma B. MiR-143 suppresses osteogenic differentiation by targeting Osterix. Mol Cell Biochem. 2014;390(1–2):69–74.

53. Liang WC, Fu WM, Wang YB, et al. H19 activates Wnt signaling and promotes osteoblast differentiation by functioning as a competing endogenous RNA. Sci Rep. 2016;6:2121.

54. Fang W, Zhang Y, Guo J, et al. Diallyl disulfide suppresses proliferation and induces apoptosis in human gastric cancer through Wnt-1 signaling pathway by up-regulation of miR-200b and miR-22. Cancer Lett. 2013;340(1):72–81.

55. Ryan BM, Robles AI, Harris CC. Genetic variation in microRNA networks: the implications for cancer research. Nat Rev Cancer. 2010;10(6):389–402.

56. Tang H, Song Y, Guo J, et al. Diallyl disulfide suppresses proliferation and induces apoptosis in human gastric cancer through Wnt-1 signaling pathway by up-regulation of miR-200b and miR-22. Cancer Lett. 2013;340(1):72–81.

57. Hashimi ST, Fulcher JA, Charg M, Gov L, Wang L, Lee M. MicroRNA profiling identifies miR-34a and miR-21 and their target genes JAG1 and WNT1 in the coordinate regulation of dendritic cell differentiation. Blood. 2009;114(2):404–14.

58. de Antonellis P, Medaglia C, Cusaneli E, et al. MiR-34a targeting of Notch ligand delta-like 1 impairs CD15+ /CD133+ tumor-propagating cells and supports neural differentiation in medulloblastoma. PLoS One. 2011;6(9):e24584.

59. Bae Y, Yang T, Zeng HC, et al. MiRNA-34c regulates Notch signaling during bone development. Hum Mol Genet. 2012;21(13):2991–3000.

60. Tian Q, Jia J, Ling S, Liu Y, Yang S, Shao Z. A causal role for circulating miR-34b in osteosarcoma. Eur J Surg Oncol. 2014;40(1):67–72.

61. Krzeszinski JY, Wei W, Huynh H, et al. miR-34a blocks osteoporosis and bone metastasis by inhibiting osteoclastogenesis and Tgfβ. Nature. 2014;512(7515):431–5.

62. Liu C, Ma XW, Zhang XJ, Shen SQ, pri-miR-34b/c rs4938723 polymorphism is associated with hepatocellular carcinoma risk: a case-control study in a Chinese population. Int J Mol Epidemiol Biomark. 2017;8(1):1–7.

63. Hashemi M, Danesh H, Bizhani F, et al. Pri-miR-34b/c rs4938723 polymorphism increased the risk of prostate cancer. Cancer Biomark. 2018;17(2):155–9.

64. Dai ZM, Kang HF, Zhang WG, et al. The associations of single nucleotide polymorphisms in miR196a2, miR-499, and miR-608 with breast cancer susceptibility: a STROBE-compliant observational study. Medicine (Baltimore). 2016;95(7):e2826.

65. Zheng L, Zhaq C, Zhao J, Ling L. Functional miR-146a, miR-149, miR-196a2 and miR-499 polymorphisms and the susceptibility to hepatocellular carcinoma: an updated meta-analysis. Clin Res Hepatol Gastroenterol. 2017;41(6):664–76.

66. Xiao Y, Bao MH, Luo HQ, Xiang J, Li J. A meta-analysis of the association between polymorphisms in microRNAs and risk of ischemic stroke. Genes (Basel). 2015;6(4):1283–99.

67. Peng S, Gao D, Gao C, Wei P, Niu M, Shuai C. MicroRNAs regulate signaling pathways in osteogenic differentiation of mesenchymal stem cells (Review). Mol Med Rep. 2017;18(2):155–9.

68. Santini P, Politi L, Vedova PD, Scandurra R, Scotto d’Abusco A. The inflammatory ciruity of miR-149 as a pathological mechanism in osteoarthritis. Rheumatol Int. 2014;34(5):711–6.

69. Chen ZZ, Zhang XD, Chen Y, Wu YB. The role of circulating miR-146a in patients with rheumatoid arthritis treated by Tripterygium wifordii Hook F. Medicine (Baltimore). 2017;96(20):e6775.

70. Cheung KS, Sposito N, Stumpf PS, Wilson DI, Sanchez-Elsner T, Orrefo RO. MicroRNA-146a regulates human foetal femur derived skeletal stem cell differentiation by down-regulating SMAD2 and SMAD3. PLoS One. 2014;9(6):e98063.

71. Jin L, Zhao J, Jing W, et al. Role of miR-146a in human chondrocyte apoptosis in response to mechanical pressure injury in vitro. Int J Mol Med. 2014;34(2):451–63.

72. Yu Y, Li X, Liu WJ, et al. [Effect of microRNA-146b-5p on adipogenesis of mouse bone marrow derived mesenchymal stem cells]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2017;25(2):541–8.
bone marrow derived skeletal stem cells and up-regulated in osteoarthritis. Sci Rep. 2017;7:46704.

78. Li X, Cao X. BMP signaling and HOX transcription factors play in limd development. Front Biosci. 2003;8:5805–12.

79. He X, Yan YL, Eberhart JK, et al. miR-196 regulates axial patterning and pectoral appendage initiation. Dev Biol. 2011;357(2):463–77.

80. Yekta S, Shih IH, Bartel DP. MicroRNA-directed cleavage of HOXB8 mRNA. Science. 2004;304(5670):594–6.

81. Kim YJ, Bae SW, Yu SS, Bae YC, Jung JS. miR-196a regulates differentiation of mesenchymal stem cells derived from human adipose tissue. J Bone Miner Res. 2009;24(5):816–25.

82. Wang P, Xie S, Cui A, Zhang Y, Jiang B. miR-196a2 polymorphisms and susceptibility to cancer: a meta-analysis involving 24,697 subjects. Exp Ther Med. 2012;3(2):324–30.

83. Song ZS, Wu Y, Zhao HG, et al. Association between the rs11614913 variant of miRNA-196a-2 and the risk of epithelial ovarian cancer. Oncol Lett. 2016;11(1):194–200.

84. Wong SF, Agarwal V, Mansfield JH, et al. Independent regulation of vertebral number and vertebral identity by microRNA-196 paralogs. Proc Natl Acad Sci U S A. 2015;112(35):E4884–93.

85. Karabegovici O, Maas S, Medina-Gomez C, et al. Genetic polymorphism of miR-196a-2 is associated with bone mineral density (BMD). Int J Mol Sci. 2017;18(12).

86. Zhang YH, Hu L, Shi G. Effects of microRNA-499 on the inflammatory damage of endothelial cells during coronary artery disease via the targeting of PDCD4 through the NF-Kappabeta/TNF-alpha signaling pathway. Cell Physiol Biochem. 2017;44(1):110–24.

87. Li K, Tie H, Hu N, et al. Association of two polymorphisms rs2910164 in miRNA-146a and rs3746444 in miRNA-499 with rheumatoid arthritis: a meta-analysis. Hum Immunol. 2014;75(7):602–8.

88. Feng Y, Duan F, Song C, Zhai X, Dai L, Cui S. Systematic evaluation of cancer risk associated with rs2292832 in miR149 and rs95819 in miR27a: a comprehensive and updated metaanalysis. Oncotarget. 2016;7(16):22368–84.

89. Seelig C, Karpinski K, Haug AT, et al. Five freely circulating miRNAs and bone tissue miRNAs are associated with osteoporotic fractures. J Bone Miner Res. 2014;29(8):1718–28.

90. Garmilla-Ezquerra P, Sanudo C, Delgado-Calle J, Perez-Nunez MI, Seeliger C, Karpinski K, Haug AT, et al. Five freely circulating miRNAs regulate osteogenic differentiation in mesenchymal stem cells derived from human adipose tissue. J Bone Miner Res. 2009;24(5):816–25.

91. Kelch S, Balmayor ER, Seeliger C, Vester H, Kirschke JS, van Eld JH, et al. Independent regulation of miR-196a-2 and the risk of epithelial ovarian cancer. Oncol Lett. 2016;11(1):194–200.

92. Wong SF, Agarwal V, Mansfield JH, et al. Independent regulation of vertebral number and vertebral identity by microRNA-196 paralogs. Proc Natl Acad Sci U S A. 2015;112(35):E4884–93.

93. Karabegovici O, Maas S, Medina-Gomez C, et al. Genetic polymorphism of miR-196a-2 is associated with bone mineral density (BMD). Int J Mol Sci. 2017;18(12).

94. Zhang YH, Hu L, Shi G. Effects of microRNA-499 on the inflammatory damage of endothelial cells during coronary artery disease via the targeting of PDCD4 through the NF-Kappabeta/TNF-alpha signaling pathway. Cell Physiol Biochem. 2017;44(1):110–24.

95. Li K, Tie H, Hu N, et al. Association of two polymorphisms rs2910164 in miRNA-146a and rs3746444 in miRNA-499 with rheumatoid arthritis: a meta-analysis. Hum Immunol. 2014;75(7):602–8.

96. Seelig C, Karpinski K, Haug AT, et al. Five freely circulating miRNAs and bone tissue miRNAs are associated with osteoporotic fractures. J Bone Miner Res. 2014;29(8):1718–28.

97. Garmilla-Ezquerra P, Sanudo C, Delgado-Calle J, Perez-Nunez MI, Seeliger C, Karpinski K, Haug AT, et al. Five freely circulating miRNAs regulate osteogenic differentiation in mesenchymal stem cells derived from human adipose tissue. J Bone Miner Res. 2009;24(5):816–25.

98. Wang P, Xie S, Cui A, Zhang Y, Jiang B. miR-196a2 polymorphisms and susceptibility to cancer: a meta-analysis involving 24,697 subjects. Exp Ther Med. 2012;3(2):324–30.

99. Song ZS, Wu Y, Zhao HG, et al. Association between the rs11614913 variant of miRNA-196a-2 and the risk of epithelial ovarian cancer. Oncol Lett. 2016;11(1):194–200.

100. Garmilla-Ezquerra P, Sanudo C, Delgado-Calle J, Perez-Nunez MI, Seeliger C, Karpinski K, Haug AT, et al. Five freely circulating miRNAs regulate osteogenic differentiation in mesenchymal stem cells derived from human adipose tissue. J Bone Miner Res. 2009;24(5):816–25.
122. Bernstein CN, Blanchard JF, Leslie W, Wajda A, Yu BN. The incidence of fracture among patients with inflammatory bowel disease. A population-based cohort study. Ann Intern Med. 2000;133(10):795–9.

123. Ding Q, Zhou H, Yun B, et al. Interleukin-13 inhibits expression of cyp27b1 in peripheral CD14+ cells that is correlated with vertebral bone mineral density of patients with ulcerative colitis. J Cell Biochem. 2017;118(2):376–81.

124. Pan W, Zhu S, Yuan M, et al. MicroRNA-21 and microRNA-148a contribute to DNA hypomethylation in lupus CD4+ T cells by directly and indirectly targeting DNA methyltransferase 1. J Immunol. 2010;184(12):6773–81.

125. Cheng P, Chen C, He HB, et al. miR-148a regulates osteoclastogenesis by targeting V-maf musculoaponeurotic fibrosarcoma oncogene homolog B. J Bone Miner Res. 2013;28(5):1180–90.

126. Moayeri A, Mohamadpour M, Mousavi SF, Shirzadpour E, Mohamadpour S, Amraei M. Fracture risk in patients with type 2 diabetes mellitus and possible risk factors: a systematic review and meta-analysis. Ther Clin Risk Manag. 2017;13:453–68.

127. Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes—a meta-analysis. Osteoporos Int. 2007;18(4):427–44.

128. Saito M, Kida Y, Kato S, Marumo K. Diabetes, collagen, and bone quality. Curr Osteoporos Rep. 2014;12(2):181–8.

129. Das S, Ferrito M, Kent OA, et al. Nuclear miRNA regulates the mitochondrial genome in the heart. Circ Res. 2012;110(12):1596–603.

130. Kalman S, Garbett KA, Verczkei A, Shelton RC, Korade Z, Mirnics K. Metabolic stress-induced microRNA and mRNA expression profiles of human fibroblasts. Exp Cell Res. 2014;320(2):343–353.

131. Kinoshita C, Aoyama K, Matsumura N, Kikuchi-Utsumi K, Watabe M, Nakaki T. Rhythmic oscillations of the microRNA miR-96-5p play a neuroprotective role by indirectly regulating glutathione levels. Nat Commun. 2014;5:3823.

132. Neer RM, Amaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344(19):1434–41.

133. Bone HG, Wagman RB, Brandi ML, et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 2017;5(7):513–23.

134. Anastasilakis AD, Makras P, Pikiolidou M, et al. Changes of circulating microRNAs in response to treatment with teriparatide or denosumab in postmenopausal osteoporosis. J Clin Endocrinol Metab. 2018;103(3):1206–13.

135. Anastasilakis AD, Yayropoulou MP, Makras P, et al. Increased osteoclastogenesis in patients with vertebral fractures following discontinuation of denosumab treatment. Eur J Endocrinol. 2017;176(6):677–83.

136. Zhang W, Wu Y, Shiozaki Y, et al. miRNA-133a-5p inhibits the expression of osteoblast differentiation-associated markers by targeting the 3’ UTR of RUNX2. DNA Cell Biol. 2018;37(3):199–209.

137. Wang H, Sun Z, Wang Y, et al. miR-33-5p, a novel mechano-sensitive microRNA promotes osteoblast differentiation by targeting Hmga2. Sci Rep. 2016;6:23170.

138. Sun Y, Xu J, Xu L, et al. MiR-503 promotes bone formation in distraction osteogenesis through suppressing Smurf1 Expression. Sci Rep. 2017;7(1):409.

139. Yoshizuka M, Nakasa T, Kawanishi Y, et al. Inhibition of microRNA-222 expression accelerates bone healing with enhancement of osteogenesis, chondrogenesis, and angiogenesis in a rat refractory fracture model. J Orthop Sci. 2016;21(6):852–8.